CNASOTCTranslatedVAXIGRIP TETRA
SANOFI
Identification
- Active ingredient (INN)
- VACCIN GRIPPAL QUADRIVALENT INACTIVE À VIRION FRAGMENTE
- Internal code
- 13 U 503
- Country of Origin
- France
- Pharmaceutical form
- Injectable Suspension
- Prescription List
- OTC
- Packaging
- b/1 seringue pre- remplie de 0.5ml
CNASDAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
Prevention of influenza, especially in subjects at high risk of associated complications.
TETRA is indicated in adults and children from 6 months of age.
The use of INFLUVAC
TETRA should be based on official recommendations.
Associated Conditions
To improve the traceability of biological drugs, the name and batch number of the administered product must be clearly recorded.
As with all injectable vaccines, appropriate medical treatment is recommended for the management of a possible anaphylactic reaction following administration of the vaccine.
TETRA should not be administered intravascularly.
As with other intramuscular vaccines, INFLUVAC TETRA should be administered with caution in people with thrombocytopenia or coagulation disorder, as bleeding may occur as a result of intramuscular administration in these people.
Anxieous reactions, including vasovagal reactions (syncopes), absorbent hyperventilation or absorbent reactions, may occur after, or even before, any vaccination as a psychogenic reaction to injection by a needle.
Anxiety reactions, including absorbent reactions (syncopes), absorbent reactions, absorbent reactions, absorbsorbsorbs of the virus.
Mechanism of Action
The following are the following: a) the patient's drug(s) is a drug(s) is a drug(s) is a drug(s) is a drug(s) is a drug(s) is a drug(s) is a drug(s) is a drug(s) is a drug(s) is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug(s) that is a drug.
Adverse Effects
The following clinical trials were conducted in two clinical trials, healthy adults aged 18 years and older and healthy children aged 3-17 years received INFLUVAC TETRA or trivalent flu vaccine INFLUVAC.
In a third clinical trial, the safety of INFLUVAC TETRA was evaluated in healthy children aged 6-35 months who received INFLUVAC TETRA or non-flu control vaccine.
In both trials, children aged 6 months to 8 years received one or two doses of INFLUVAC TETRA based on their history of influenza vaccination received a clinical event.
The most common adverse reactions were those of the adverse effects of the adverse effects of the adverse effects of the adverse effects of the adverse effects of the adverse effects of the adverse effects of the adverse effects of the adverse effects of the adverse effects of the adverse effects of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions of the adverse reactions.